A genetic network model of cellular responses to lithium treatment and cocaine abuse in bipolar disorder

BMC Systems Biology

Volumn 4, Issue , 2010, Pages

  McEachin, Richard C ^a,b   Chen, Haiming ^a   Sartor, Maureen A ^b   Saccone, Scott F ^c   Keller, Benjamin J ^b,d   Prossin, Alan R ^a   Cavalcoli, James D ^b   McInnis, Melvin G ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d EASTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM;

ADULT; ARTICLE; BIOLOGICAL MODEL; BIPOLAR DISORDER; BRAIN; CELL LINE; COCAINE DEPENDENCE; DNA MICROARRAY; DRUG EFFECT; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; TREATMENT OUTCOME;

ADULT; BIPOLAR DISORDER; BRAIN; CELL LINE; COCAINE-RELATED DISORDERS; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; LITHIUM; MALE; MIDDLE AGED; MODELS, GENETIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TREATMENT OUTCOME;

EID: 78349252734     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-4-158     Document Type: Article

References (79)

1. Escamilla MA, Zavala JM. Genetics of bipolar disorder. Dialogues Clin Neurosci 2008, 10:141-152.
2. Storosum JG, Wohlfarth T, Schene A, Elferink A, van Zwieten BJ, van den Brink W. Magnitude of effect of lithium in short-term efficacy studies of moderate to severe manic episode. Bipolar Disord 2007, 9:793-798.
3. Alda M, Grof P, Rouleau GA, Turecki G, Young LT. Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:1038-1045.
4. Rowe MK, Chuang DM. Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 2004, 6:1-18.
5. Ruzickova M, Turecki G, Alda M. Pharmacogenetics and mood stabilization in bipolar disorder. Am J Med Genet C Semin Med Genet 2003, 123C:18-25.
6. Taib Z. Statistical analysis of oligonucleotide microarray data. C R Biol 2004, 327:175-180.
7. Niculescu AB, Kelsoe JR. Convergent functional genomics: application to bipolar disorder. Ann Med 2001, 33:263-271.
8. Zhou X, Barrett TB, Kelsoe JR. Promoter variant in the GRK3 gene associated with bipolar disorder alters gene expression. Biol Psychiatry 2008, 64:104-110.
9. Kim S, Choi KH, Baykiz AF, Gershenfeld HK. Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex. BMC Genomics 2007, 8:413.
10. Huff MO, Li XP, Ginns E, El-Mallakh RS. Effect of ethacrynic acid on the sodium- and potassium-activated adenosine triphosphatase activity and expression in Old Order Amish bipolar individuals. J Affect Disord 2010, 123:303-307.
11. Sugawara H, Iwamoto K, Bundo M, Ishiwata M, Ueda J, Kakiuchi C, Ishigooka J, Kato T. Effect of mood stabilizers on gene expression in lymphoblastoid cells. J Neural Transm 2010, 117:155-164.
12. Washizuka S, Iwamoto K, Kakiuchi C, Bundo M, Kato T. Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. Neurosci Res 2009, 63:199-204.
13. Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986, 73:320-326.
14. Editor in the field. The Coriell Institute for Medical Research. Nat Genet 2005, 37:2.
15. Schulze TG, Buervenich S, Badner JA, Steele CJ, Detera-Wadleigh SD, Dick D, Foroud T, Cox NJ, MacKinnon DF, Potash JB, et al. Loci on chromosomes 6q and 6p interact to increase susceptibility to bipolar affective disorder in the national institute of mental health genetics initiative pedigrees. Biol Psychiatry 2004, 56:18-23.
16. Brady KT, Lydiard RB. Bipolar affective disorder and substance abuse. J Clin Psychopharmacol 1992, 12:17S-22S.
17. Sartor MA, Tomlinson CR, Wesselkamper SC, Sivaganesan S, Leikauf GD, Medvedovic M. Intensity-based hierarchical Bayes method improves testing for differentially expressed genes in microarray experiments. BMC Bioinformatics 2006, 7:538.
18. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:Article3.
19. Blalock EM, Chen KC, Stromberg AJ, Norris CM, Kadish I, Kraner SD, Porter NM, Landfield PW. Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: statistical reliability and functional correlation. Ageing Res Rev 2005, 4:481-512.
20. Zhuo D, Zhao WD, Wright FA, Yang HY, Wang JP, Sears R, Baer T, Kwon DH, Gordon D, Gibbs S, et al. Assembly, annotation, and integration of UNIGENE clusters into the human genome draft. Genome Res 2001, 11:904-918.
21. Keller BJ, McEachin RC. Identifying hypothetical genetic influences on complex disease phenotypes. BMC Bioinformatics 2009, 10(Suppl 2):S13.
22. McEachin RC, Keller BJ, Zandi PP, Almani M, McInnis MG. Prioritizing Disease Genes by Analysis of Common Elements (PDG-ACE). AMIA Annu Symp Proc 2007, 1068.
23. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006, 67:247-257.
24. Raychaudhuri S, Plenge RM, Rossin EJ, Ng AC, Purcell SM, Sklar P, Scolnick EM, Xavier RJ, Altshuler D, Daly MJ. Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. PLoS Genet 2009, 5:e1000534.
25. States DJ, Ade AS, Wright ZC, Bookvich AV, Athey BD. MiSearch adaptive pubMed search tool. Bioinformatics 2009, 25:974-976.
26. Dezso Z, Nikolsky Y, Nikolskaya T, Miller J, Cherba D, Webb C, Bugrim A. Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst Biol 2009, 3:36.
27. Sartor MA, Mahavisno V, Keshamouni VG, Cavalcoli J, Wright Z, Karnovsky A, Kuick R, Jagadish HV, Mirel B, Weymouth T, et al. ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics 2010, 26:456-463.
28. Becker KG, Barnes KC, Bright TJ, Wang SA. The genetic association database. Nat Genet 2004, 36:431-432.
29. Huang da W, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 2007, 35:W169-175.
30. Saccone SF, Saccone NL, Swan GE, Madden PA, Goate AM, Rice JP, Bierut LJ. Systematic biological prioritization after a genome-wide association study: an application to nicotine dependence. Bioinformatics 2008, 24:1805-1811.
31. Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, et al. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol 2009, 27:1005-1011.
32. Najt P, Perez J, Sanches M, Peluso MA, Glahn D, Soares JC. Impulsivity and bipolar disorder. Eur Neuropsychopharmacol 2007, 17:313-320.
33. Hellemans KG, Nobrega JN, Olmstead MC. Early environmental experience alters baseline and ethanol-induced cognitive impulsivity relationship to forebrain 5-HT1A receptor binding. Behav Brain Res 2005, 159:207-220.
34. Albanese MJ, Clodfelter RC, Pardo TB, Ghaemi SN. Underdiagnosis of bipolar disorder in men with substance use disorder. J Psychiatr Pract 2006, 12:124-127.
35. Bauer MS, Altshuler L, Evans DR, Beresford T, Williford WO, Hauger R. Prevalence and distinct correlates of anxiety substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. J Affect Disord 2005, 85:301-315.
36. Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord 2001, 3:181-188.
37. Chengappa KN, Levine J, Gershon S, Kupfer DJ. Lifetime prevalence of substance or alcohol abuse and dependence among subjects with bipolar I and II disorders in a voluntary registry. Bipolar Disord 2000, 2:191-195.
38. Fenn HH, Bauer MS, Altshuler L, Evans DR, Williford WO, Kilbourne AM, Beresford TP, Kirk G, Stedman M, Fiore L. Medical comorbidity and health-related quality of life in bipolar disorder across the adult age span. J Affect Disord 2005, 86:47-60.
39. McElroy SL, Altshuler LL, Suppes T, Keck PE, Frye MA, Denicoff KD, Nolen WA, Kupka RW, Leverich GS, Rochussen JR, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001, 158:420-426.
40. Pini S, Dell'Osso L, Mastrocinque C, Marcacci G, Papasogli A, Vignoli S, Pallanti S, Cassano G. Axis I comorbidity in bipolar disorder with psychotic features. Br J Psychiatry 1999, 175:467-471.
41. Sonne SC, Brady KT, Morton WA. Substance abuse and bipolar affective disorder. J Nerv Ment Dis 1994, 182:349-352.
42. Ringen PA, Melle I, Birkenaes AB, Engh JA, Faerden A, Jonsdottir H, Nesvag R, Vaskinn A, Friis S, Larsen F, et al. Illicit drug use in patients with psychotic disorders compared with that in the general population a cross-sectional study. Acta Psychiatr Scand 2008, 117:133-138.
43. Xing G, Zhang L, Russell S, Post R. Reduction of dopamine-related transcription factors Nurr1 and NGFI-B in the prefrontal cortex in schizophrenia and bipolar disorders. Schizophr Res 2006, 84:36-56.
44. Buervenich S, Carmine A, Arvidsson M, Xiang F, Zhang Z, Sydow O, Jonsson EG, Sedvall GC, Leonard S, Ross RG, et al. NURR1 mutations in cases of schizophrenia and manic-depressive disorder. Am J Med Genet 2000, 96:808-813.
45. Al Banchaabouchi M, Pena de Ortiz S, Menendez R, Ren K, Maldonado-Vlaar CS. Chronic lithium decreases Nurr1 expression in the rat brain and impairs spatial discrimination. Pharmacol Biochem Behav 2004, 79:607-621.
46. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010, 15(4):384-92.
47. St Andre J, Albanos K, Reilly S. C-fos expression in the rat brain following lithium chloride-induced illness. Brain Res 2007, 1135:122-128.
48. Spencer CM, Houpt TA. Dynamics of c-fos and ICER mRNA expression in rat forebrain following lithium chloride injection. Brain Res Mol Brain Res 2001, 93:113-126.
49. Hamamura T, Lee Y, Ohashi K, Fujiwara Y, Miki M, Suzuki H, Kuroda S. A low dose of lithium chloride selectively induces Fos protein in the central nucleus of the amygdala of rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24:285-294.
50. Portillo F, Carrasco M, Vallo JJ. c-fos expression in the rat hypothalamic paraventricular nucleus induced by LiCl: descending projections to the dorsal vagal motor nucleus. Rev Esp Fisiol 1997, 53:361-366.
51. Bunney WE. The current status of research in the catecholamine theories of affective disorders. Psychopharmacol Commun 1975, 1:599-609.
52. Perrone-Capano C, Di Porzio U. Genetic and epigenetic control of midbrain dopaminergic neuron development. Int J Dev Biol 2000, 44:679-687.
53. Wallen A, Perlmann T. Transcriptional control of dopamine neuron development. Ann N Y Acad Sci 2003, 991:48-60.
54. Bannon MJ, Pruetz B, Barfield E, Schmidt CJ. Transcription factors specifying dopamine phenotype are decreased in cocaine users. Neuroreport 2004, 15:401-404.
55. Bannon MJ, Pruetz B, Manning-Bog AB, Whitty CJ, Michelhaugh SK, Sacchetti P, Granneman JG, Mash DC, Schmidt CJ. Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers. Proc Natl Acad Sci USA 2002, 99:6382-6385.
56. Lemberger T, Parkitna JR, Chai M, Schutz G, Engblom D. CREB has a context-dependent role in activity-regulated transcription and maintains neuronal cholesterol homeostasis. Faseb J 2008, 22:2872-2879.
57. Leo D, di Porzio U, Racagni G, Riva MA, Fumagalli F, Perrone-Capano C. Chronic cocaine administration modulates the expression of transcription factors involved in midbrain dopaminergic neuron function. Exp Neurol 2007, 203:472-480.
58. Misiuta IE, Saporta S, Sanberg PR, Zigova T, Willing AE. Influence of retinoic acid and lithium on proliferation and dopaminergic potential of human NT2 cells. J Neurosci Res 2006, 83:668-679.
59. Flemenbaum A. Antagonism of behavioral effects of cocaine by lithium. Pharmacol Biochem Behav 1977, 7:83-85.
60. Mandell AJ, Knapp S. Current research in the indoleamine hypothesis of affective disorders. Psychopharmacol Commun 1975, 1:587-597.
61. Mandell AJ, Knapp S. A neurobiological model for the symmetrical prophylactic action of lithium in bipolar affective disorder. Pharmakopsychiatr Neuropsychopharmakol 1976, 9:116-126.
62. Gawin FH, Kleber HD. Cocaine abuse treatment. Open pilot trial with desipramine and lithium carbonate. Arch Gen Psychiatry 1984, 41:903-909.
63. Kleber H, Gawin F. Psychopharmacological trials in cocaine abuse treatment. Am J Drug Alcohol Abuse 1986, 12:235-246.
64. Nunes EV, McGrath PJ, Wager S, Quitkin FM. Lithium treatment for cocaine abusers with bipolar spectrum disorders. Am J Psychiatry 1990, 147:655-657.
65. Zahm DS, Becker ML, Freiman AJ, Strauch S, Degarmo B, Geisler S, Meredith GE, Marinelli M. Fos after single and repeated self-administration of cocaine and saline in the rat: emphasis on the Basal forebrain and recalibration of expression. Neuropsychopharmacology 2010, 35:445-463.
66. McEachin RC, Saccone NL, Saccone SF, Kleyman-Smith YD, Kar T, Kare RK, Ade AS, Sartor MA, Cavalcoli JD, McInnis MG. Modeling complex genetic and environmental influences on comorbid bipolar disorder with tobacco use disorder. BMC Med Genet 2010, 11:14.
67. McEachin RC, Keller BJ, Saunders EF, McInnis MG. Modeling gene-by-environment interaction in comorbid depression with alcohol use disorders via an integrated bioinformatics approach. BioData Min 2008, 1:2.
68. Pregelj P. Psychosis and depression - a neurobiological view. Psychiatr Danub 2009, 21(Suppl 1):102-105.
69. Hammonds MD, Shim SS. Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 2009, 105:113-119.
70. Mattai A, Fung L, Bakalar J, Overman G, Tossell J, Miller R, Rapoport J, Gogtay N. Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children. Hum Psychopharmacol 2009, 24:584-589.
71. Focosi D, Azzara A, Kast RE, Carulli G, Petrini M. Lithium and hematology: established and proposed uses. J Leukoc Biol 2009, 85:20-28.
72. O'Reilly EJ, Mirzaei F, Forman MR, Ascherio A. Diethylstilbestrol exposure in utero and depression in women. Am J Epidemiol 2010, 171:876-882.
73. Saunders EJ. Physical and psychological problems associated with exposure to diethylstilbestrol (DES). Hosp Community Psychiatry 1988, 39:73-77.
74. Choi SH, Shapiro H, Robinson GE, Irvine J, Neuman J, Rosen B, Murphy J, Stewart D. Psychological side-effects of clomiphene citrate and human menopausal gonadotrophin. J Psychosom Obstet Gynaecol 2005, 26:93-100.
75. Gallagher P, Malik N, Newham J, Young AH, Ferrier IN, Mackin P. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev 2008, CD005168.
76. Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci 2009, 1179:41-55.
77. Schule C, Baghai TC, Eser D, Hafner S, Born C, Herrmann S, Rupprecht R. The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. PLoS One 2009, 4:e4324.
78. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010, 67:432-438.
79. Clerici M, Arosio B, Mundo E, Cattaneo E, Pozzoli S, Dell'osso B, Vergani C, Trabattoni D, Altamura AC. Cytokine polymorphisms in the pathophysiology of mood disorders. CNS Spectr 2009, 14:419-425.